We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Boston Scientific (BSX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Boston Scientific is a member of the Medical sector. This group includes 999 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Boston Scientific is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for BSX's full-year earnings has moved 2.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that BSX has returned about 15.1% since the start of the calendar year. At the same time, Medical stocks have lost an average of 4.4%. As we can see, Boston Scientific is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Dare Bioscience, Inc. (DARE - Free Report) . The stock has returned 4.5% year-to-date.
For Dare Bioscience, Inc. the consensus EPS estimate for the current year has increased 8.2% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, Boston Scientific is a member of the Medical - Products industry, which includes 83 individual companies and currently sits at #135 in the Zacks Industry Rank. This group has gained an average of 5.8% so far this year, so BSX is performing better in this area.
In contrast, Dare Bioscience, Inc. falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 503 stocks and is ranked #72. Since the beginning of the year, the industry has moved -3.9%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Boston Scientific and Dare Bioscience, Inc. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Boston Scientific (BSX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Boston Scientific is a member of the Medical sector. This group includes 999 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Boston Scientific is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for BSX's full-year earnings has moved 2.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that BSX has returned about 15.1% since the start of the calendar year. At the same time, Medical stocks have lost an average of 4.4%. As we can see, Boston Scientific is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Dare Bioscience, Inc. (DARE - Free Report) . The stock has returned 4.5% year-to-date.
For Dare Bioscience, Inc. the consensus EPS estimate for the current year has increased 8.2% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, Boston Scientific is a member of the Medical - Products industry, which includes 83 individual companies and currently sits at #135 in the Zacks Industry Rank. This group has gained an average of 5.8% so far this year, so BSX is performing better in this area.
In contrast, Dare Bioscience, Inc. falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 503 stocks and is ranked #72. Since the beginning of the year, the industry has moved -3.9%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Boston Scientific and Dare Bioscience, Inc. as they could maintain their solid performance.